CNP 2018 HeaderPartners
CNP 2018 Mobile Header

2018 Preliminary Agenda

Event Overview

Now in its 13th year, the Neurotech Investing & Partnering Conference is the premier business and investment conference for commercial neuroscience including pharmaceuticals, medical devices, diagnostics and neurosoftware. The conference features keynotes, investor panels, cutting-edge company presentations, and panel discussions on a comprehensive selection of neurotech topics. Our goal is to provide a highly interactive environment where cutting-edge technologies, devices, drugs and therapies inspire new collaborations and secure financing to navigate the development path and ultimately reach patients.

Welcome Keynote and State of the Neurotechnology Industry
The Neurotechnology Industry Organization and guest speakers provide an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics.
Panelist: Alison Fenney, Executive Director, NIO

Investing in Neurotech Panel
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Josh Pinto, Vice President, Healthcare Investment Banking, Credit Suisse
Panelists: Rahul Ballal, Entrepreneur-in-Residence, Versant Ventures
Laura Tadvalkar, Senior Associate, MP Health Partners

Treatments for Alzheimer’s and Cognitive Disorders
As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?
Panelist: Christopher U. Missling, CEO, Anavex

Developments on the Horizon for Pain and Epilepsy
Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain. Hear from leading companies on their approaches.
Panelist: Shashidhar H. Kori, CSO, Trigemina

Internal and External Research and Development
Pharmaceutical and Device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will be kept in house or partnered. This panel of experts will discuss how they approach collaborations with other companies, academic groups, research institutes, and platform companies.
Panelists: Jeff Erb, Senior Director, Strategy and Business Development, Medtronic
Isaacs Veinberg, Head External Innovation, Sanofi
Fernando Salles Vice President, Head of Global Search, Teva Pharmaceuticals
Eric Schaeffer, Senior Director of Neuroscience Innovation, Johnson & Johnson Innovation

Strategies in CNS Drug and Device Development
Intelligent trial design, incorporation of commercial inputs into clinical development fundraising, and business development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.

Partnering and Licensing in Neurotech Panel
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for inlicensing novel therapeutics, devices and diagnostics and what they look for in a partner.
Panelists: Mural Gopalakrishnan, Head of Neuroscience Search and Evaluation, AbbVie
Robert Bagdorf, Vice President, Biopharmaceuticals Search and Evaluation, Pfizer

Parkinson’s and other Movement Disorders
Current treatments for movement disorders can improve functioning but suffer from side effects and “off” period especially as the disease progresses. A number of novel pipeline pharmaceuticals and devices seek to address these issues. This session will explore how disease modifying treatments alter the course of movement disorders and how companion diagnostics can be leveraged to provide the most optimal outcomes for patients.

Next Generation Psychiatry
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging. Novel devices and diagnostics are poised to change the treatment landscape. This session will gather the most innovative treatments for mental health disorders.
Moderator: Manuel Lopez Figueroa, Venture Partner, Bay City Capital
Panelist: Remy Luthinger, CEO, Minerva Neurosciences

Frontiers in Neurotechnology
In this session, we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets. Closed loop systems create the promise of reduced side effects and more targeted treatment. New technology is yielding benefits in delivery of therapeutics to brain. This session will preview of next generation products and companies in neurotechnology.
Panelists: Abhishek Datta, CTO, Soterix
Susan Rosenbaum, Founder and CEO, Lauren Sciences

Challenges in Brain Trauma
Posttraumatic stress disorder (PTSD), traumatic brain injury (TBI), stroke and other trauma have devastating consequences to the brain. This session will explore novel approaches for early detection and treatment of brain trauma to minimize sequela and improve recovery.
Panelists: Rick Doblin, Executive Director, MAPS
Dan Kincade, CEO, Sense Diagnostics

Targeting Orphan Diseases
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments for ALS, lysosomal storage disorders, Huntington’s, and more.
Panelist: Marc Martinell, CEO, Minoryx




For more details on the conference, please contact:
Carla Lema Tome
Neurotechnology Industry Organization
Phone: 321-626-9558
Email: carla@neurotechindustry.org

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  




Corporate Sponsor

Neuroscience Trials Australia




NIO


Cambridge Health Tech